RANCHO CUCAMONGA, Calif., Nov. 29, 2017 — Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that today the U.S. Food and Drug Administration (“FDA”) granted approval of two abbreviated new drug applications (ANDAs) for Medroxyprogesterone Acetate Injectable Suspension, USP, 150 mg/mL, 1mL vial, and 1mL prefilled syringe, respectively, indicated for the prevention of pregnancy. Amphastar’s newly approved products were determined by the FDA to be therapeutically equivalent to Depo-Provera® Contraceptive Injection sold in the United States by Pfizer.Pipeline InformationForward Looking Statements
Powered by WPeMatico